Abbott Diagnostics Business Revenue and Competitors
Estimated Revenue & Valuation
- Abbott Diagnostics Business's estimated annual revenue is currently $2.7B per year.
- Abbott Diagnostics Business's estimated revenue per employee is $378,000
Employee Data
- Abbott Diagnostics Business has 7209 Employees.
Abbott Diagnostics Business Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.9M | 57 | -30% | N/A | N/A |
#2 | $4.9M | 26 | -4% | N/A | N/A |
#3 | $142.1M | 421 | 8% | N/A | N/A |
#4 | $9.9M | 46 | 5% | N/A | N/A |
#5 | $165.7M | 491 | 5% | N/A | N/A |
#6 | $607.1M | 1606 | 5% | N/A | N/A |
#7 | $7.8M | 36 | 6% | N/A | N/A |
#8 | $10.4M | 48 | -11% | N/A | N/A |
#9 | $52M | 175 | 7% | N/A | N/A |
#10 | $529.2M | 1400 | 10% | N/A | N/A |
What Is Abbott Diagnostics Business?
Achieve measurably better healthcare performance with our personalized solutions consisting of resourceful advocates, harmonized systems, and intelligent insights.
keywords:N/A
N/A
Total Funding
7209
Number of Employees
$2.7B
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Abbott Diagnostics Business News
2022-04-20 - What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
... new COVID variants are expected to have accelerated COVID-19 testing globally, giving a boost to Abbott's Diagnostics business revenues.
2022-04-20 - Congenital Heart Disease Market May See Big Move | Abbott ...
The several market players and emerging companies that are profiled in the Congenital ... Abbott Diagnostics, Array BioPharma, AstraZeneca,...
2022-03-30 - Abbott awarded $1B US Army contract for COVID-19 antigen ...
Diagnostics companies including Abbott and Quidel have been scaling up production in an attempt to meet the testing demand.
Other Companies in Lake Forest
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 21516 | 4% | N/A |
#2 | $12600M | 22184 | N/A | N/A |
#3 | $17112M | 25532 | -1% | N/A |
#4 | $18300M | 26603 | 10% | $800M |